American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Emergent BioSolutions Inc. (EBS)

$6.23 +0.00% NYSE: EBS · 15-min delayed

GAITHERSBURG, Maryland
Public · NYSE: EBS
900 employees
Founded 1998

Visit website Follow

$374.6MMarket cap

$742.9MRevenue · FY2025

$52.6MNet income

900Employees

EBSNYSE

2006IPO

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1998
Type: Public · NYSE: EBS
Employees: 900
IPO date: Nov 15, 2006
Headquarters: 300 PROFESSIONAL DR
GAITHERSBURG, Maryland 20879
Phone: 240-631-3200
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300YW6TUOX8BE5103

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: EBS NYSE
SEC CIK: 1367644
LEI: 549300YW6TUOX8BE5103
EIN: 141902018
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Emergent BioSolutions Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/emergent-biosolutions-inc/"><img src="https://americancompanies.com/badge/emergent-biosolutions-inc.svg" alt="Emergent BioSolutions Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Emergent BioSolutions Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $742.9M
Net income: $52.6M
Total assets: $1.3B
Market cap: $374.6M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: EBS

$6.23 +0.00%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.45 $13.90

52-week range

Market cap: $374.6M
Shares outstanding: 60.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 15, 2006

Emergent BioSolutions Inc. (EBS) Stock Price

Profitable — net income of $52.6M in FY2025.
Trading 55% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

Peers & competitors

JOHNSON & JOHNSONJNJ

No reviews yet. Be the first to review Emergent BioSolutions Inc..

Write a review

Newsroom

News about Emergent BioSolutions Inc.

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? Zacks Investment Research · 2026-10-06 · neutral INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS GlobeNewswire Inc. · 2026-09-23 · negative Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider GlobeNewswire Inc. · 2026-09-10 · positive INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS GlobeNewswire Inc. · 2026-09-08 · negative Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks GlobeNewswire Inc. · 2026-02-12 · positive Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies GlobeNewswire Inc. · 2026-01-23 · positive

News & sentiment via Polygon.io

FAQ

Emergent BioSolutions Inc.: frequently asked questions

Is Emergent BioSolutions Inc. an American company?

Emergent BioSolutions Inc. is a US-based company headquartered in Gaithersburg, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Emergent BioSolutions Inc. headquartered?

Emergent BioSolutions Inc. is headquartered in Gaithersburg, Maryland, United States.

Is Emergent BioSolutions Inc. publicly traded?

Yes — Emergent BioSolutions Inc. is a publicly traded company. Its stock trades under the ticker symbol EBS on the NYSE.

What does Emergent BioSolutions Inc. do?

Emergent BioSolutions Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Emergent BioSolutions Inc. founded?

Emergent BioSolutions Inc. was founded in 1998.

Explore